NKGen Biotech (NKGN) Competitors $0.13 -0.01 (-7.02%) As of 02:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKGN vs. CLSD, MIRA, ASBP, RLYB, ENLV, NEUP, FBLG, NNVC, ALVR, and PMNShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Clearside Biomedical (CLSD), MIRA Pharmaceuticals (MIRA), Aspire Biopharma (ASBP), Rallybio (RLYB), Enlivex Therapeutics (ENLV), Neuphoria Therapeutics (NEUP), FibroBiologics (FBLG), NanoViricides (NNVC), AlloVir (ALVR), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Its Competitors Clearside Biomedical MIRA Pharmaceuticals Aspire Biopharma Rallybio Enlivex Therapeutics Neuphoria Therapeutics FibroBiologics NanoViricides AlloVir Promis Neurosciences Clearside Biomedical (NASDAQ:CLSD) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Do analysts recommend CLSD or NKGN? Clearside Biomedical presently has a consensus price target of $63.00, indicating a potential upside of 1,667.18%. Given Clearside Biomedical's stronger consensus rating and higher probable upside, research analysts plainly believe Clearside Biomedical is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearside Biomedical 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, CLSD or NKGN? Clearside Biomedical has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Is CLSD or NKGN more profitable? NKGen Biotech has a net margin of 0.00% compared to Clearside Biomedical's net margin of -665.19%. Company Net Margins Return on Equity Return on Assets Clearside Biomedical-665.19% N/A -124.15% NKGen Biotech N/A N/A -479.36% Does the media prefer CLSD or NKGN? In the previous week, Clearside Biomedical had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for Clearside Biomedical and 1 mentions for NKGen Biotech. NKGen Biotech's average media sentiment score of 0.00 beat Clearside Biomedical's score of -0.02 indicating that NKGen Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clearside Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NKGen Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, CLSD or NKGN? Clearside Biomedical has higher revenue and earnings than NKGen Biotech. Clearside Biomedical is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearside Biomedical$4.17M67.18-$34.35M-$0.37-9.64NKGen BiotechN/AN/A-$82.94M-$2.45-0.05 Do insiders & institutionals have more ownership in CLSD or NKGN? 18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 6.7% of Clearside Biomedical shares are owned by company insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryClearside Biomedical beats NKGen Biotech on 9 of the 14 factors compared between the two stocks. Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$5.96M$291.00M$5.70B$21.42BDividend YieldN/AN/A5.72%3.49%P/E Ratio-0.03N/A75.8829.84Price / SalesN/A431.27492.6769.96Price / CashN/A22.4425.8118.13Price / Book-0.0510.4612.834.61Net Income-$82.94M-$111.61M$3.28B$998.80M7 Day PerformanceN/A-2.08%0.17%1.09%1 Month Performance-5.36%3.56%4.54%4.46%1 Year Performance-82.22%-14.26%68.32%14.45% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen Biotech0.134 of 5 stars$0.13-7.0%N/A-82.9%$5.96MN/A-0.03N/AGap DownCLSDClearside Biomedical2.3629 of 5 stars$0.34+0.8%$4.20+1,140.0%-78.6%$26.39M$4.17M-0.9230Stock SplitMIRAMIRA Pharmaceuticals3.0281 of 5 stars$1.41+2.2%$17.00+1,105.7%+2.2%$26.32MN/A-2.882News CoveragePositive NewsShort Interest ↓ASBPAspire BiopharmaN/A$0.43-15.9%N/AN/A$25.34MN/A0.00N/APositive NewsGap UpRLYBRallybio3.2637 of 5 stars$0.58-1.9%$5.00+758.1%-47.5%$24.83M$640K-0.6240Positive NewsShort Interest ↓ENLVEnlivex Therapeutics2.5431 of 5 stars$1.03-1.0%$10.00+870.9%-32.2%$24.60MN/A-1.7870NEUPNeuphoria Therapeutics2.5943 of 5 stars$15.10+16.2%$21.00+39.1%N/A$24.42M$10K0.00N/AFBLGFibroBiologics3.4268 of 5 stars$0.54-5.5%$13.00+2,315.0%-83.5%$23.85MN/A-1.5010NNVCNanoViricides0.2161 of 5 stars$1.46+1.4%N/A-9.9%$23.47MN/A-2.0320Gap UpALVRAlloVirN/A$4.64+0.4%N/A-77.5%$23.40MN/A-0.23110Gap DownHigh Trading VolumePMNPromis Neurosciences3.6641 of 5 stars$0.42-3.7%$4.33+929.3%-66.0%$22.64MN/A-2.005Positive NewsShort Interest ↓Gap Up Related Companies and Tools Related Companies Clearside Biomedical Alternatives MIRA Pharmaceuticals Alternatives Aspire Biopharma Alternatives Rallybio Alternatives Enlivex Therapeutics Alternatives Neuphoria Therapeutics Alternatives FibroBiologics Alternatives NanoViricides Alternatives AlloVir Alternatives Promis Neurosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NKGN) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
